AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

Featured AAM All Access Podcast: Mary Beth Powers

AAM CEO Dan Leonard talks with Mary Beth Powers, President and CEO of AAM Associate Member Catholic Medical Mission Board (CMMB). With its focus on women and children, CMMB provides long-term care and medicines to communities around the world affected by poverty and unequal access to health care.

Listen to Podcast
Who’s Profiting from Your Prescription?

Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Learn More
What Are GDUFA and BsUFA User Fees?

Watch this this video to learn more about how the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Act (BsUFA) help to get more generic and biosimilar medicines to patients more quickly.
Watch Video
AAM Calls on FTC to Investigate PBM Business Practices

“A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients,” said AAM CEO Dan Leonard.

Read Press Release
Generic Medicines Are Saving Your State Billions

In 2020, generic and biosimilar medicines saved America's patients $338 billion. Find out how much your state saved with our interactive savings map.

View Interactive Map
Prescription for State Savings

State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.

Learn More
AAM Voices of Access

Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

View Report

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Jun 13, 2022 | Erica Klinger

AAM Code of Business Ethics

Jun 7, 2022 | Erica Klinger

The Hatch-Waxman 180-Day Exclusivity Incentive Accelerates Patient Access to First Generics

Drug manufacture

Jun 6, 2022 | Allen Goldberg

Giuseppe Randazzo Joins AAM as Vice President, Sciences and Regulatory Affairs

Video

Jun 3, 2022 | Erica Klinger

GDUFA and BsUFA User Fees

Video

May 31, 2022 | Erica Klinger

Teva USA is #RemarkablyGeneric

Biosimilars Patient Resource Center

May 31, 2022 | Erica Klinger

Everything You Need to Know About Biosimilars – All in One Place